2月20日 - ** 医疗保健公司OrganonOGN.N股价盘前上涨3.5%至7.78美元
** 该公司称，一项独立审查发现，该公司在记录早期生物仿制药采购情况方面没有不当行为，生物仿制药是复杂生物药的低成本版本。
** 该公司称，董事会审计委员会在对过去购买生物仿制药的时间安排提出关切后启动了审查；审查发现没有必要修改过去向美国证券交易委员会提交的文件
** 公司称将按时提交 2025 年年度报告
** 2025 年股价下跌 ~52%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.